Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06525519 | Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis | PHASE3 | NOT YET_RECRUITING | 104 | — | — | Jul 31, 2024 | Jul 31, 2026 | Jul 29, 2024 | 5 | China |
aGVHD was graded according to standard criteria
| Arm | Type | Description |
|---|---|---|
| ATLG-20 mg/kg | EXPERIMENTAL | ATLG 20mg/kg group refers to treatment with ATLG in the total dose of 20mg/kg. |
| ATLG-30mg/kg | EXPERIMENTAL | ATLG 30mg/kg group refers to treatment with ATLG in the total dose of 30mg/kg. |
| Name | Type | Description |
|---|---|---|
| ATLG | DRUG | 5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis. |
Inclusion Criteria: * 1，Age ≥ 16 and ≤ 65 years 2, Patients undergoing Haplo-identical hematopoietic stem cell transplantation 3, AML and ALL in complete cytologic response or MDS requiring allogeneic stem cell transplantation 4, ECOG performance status ≤ 2 Exclusion Criteria: * 1，Pregnant or lac...